TD Cowen analyst Joshua Jennings reiterated a Buy rating and $7.50 price target on Humacyte (NASDAQ: HUMA).The analyst commented, "Preclinical ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE